CIOInsider India Magazine

As Artificial Integration (AI) has become a matter of survival in the business realm, it’s no wonder that companies are scrambling to integrate AI into their operations. This adoption enhances decision-making, keeps businesses competitive, and fuels a thriving market for AI-driven solutions. However, it is quite challenging to find a trustworthy and reliable AI company that is committed to being the go-to partner for AI-driven digital transformation.

Thanks to a sophisticated team of AI experts with a cumulative AI experience of over three decades, COGNIFAI is addressing these challenges in an impressive manner. Guided by their core values embodied in THRIVE, the foundation that guides every decision, partnership, and innovation, they are committed to building trust, fostering inclusivity, and delivering meaningful impact for their clients, team, and community.

COGNIFAI,a fast-growing AI company based in Ahmedabad, was co-founded by Hemang Naik (CEO), Diana Priyadharshini (COO), and Romesh Sheth (CTO). Under their aegis, the company delivers intelligent, impactful, and scalable AI solutions tailored for the pharmaceutical and life sciences sectors.

Backed by a strong foundation in AI and a deep understanding of healthcare domain challenges, COGNIFAI has created its flagship platforms such as CoVigilAI, aimed at transforming the life cycle of Pharmacovigilance for Pharma and CliniWiseAI, which provides AI and ML solutions tailored to all stages of clinical trials.

Focused on quality, compliance, and patient safety, the company is piloting a mission to democratize AI for organizations of all sizes to streamline operations, reduce risk, and unlock new efficiencies in pharmacovigilance and clinical trial management. We recently interviewed the team, and the highlights of our conversation are below.

Could you describe the journey of COGNIFAI since its inception and its market positioning today?

COGNIFAI was established by three experienced professionals, each with over 11 years of expertise in AI, having worked at prominent IT firms such as Infosys and Tech Mahindra. Our extensive exposure to AI transformations across various industries allowed us to democratize Generative AI adoption across businesses of all scales. Inspired by this potential, we founded COGNIFAI to enable all businesses to unlock the power of AI.

We strategically focus on life sciences and pharmacy, leveraging our deep domain knowledge and recognizing the vast opportunities for AI innovation in these fields. COGNIFAI aims to deliver high-impact AI solutions tailored to the unique requirements of its diverse clientele. Its solutions have risen to prominence in the pharmacy sector, particularly in Pharmacovigilance and clinical operations, empowering clients to achieve operational excellence through AI. A steadfast commitment to quality and strict adherence to compliance and pharmaceutical industry standards strengthen COGNIFAI's success.

Tell us about your flagship products, CoVigilAI and CliniWiseAI.
Both the CoVigilAI and CliniWiseAI, developed during the early phase of our organization, focus on the Core Values of THRIVE. For us, quality is beyond delivering defect-free products, i.e., providing an exceptional customer experience with ease of use, improved efficiency, and smarter delivery powered by AI & Generative AI. Another aspect is compliance, which ensures complete audit readiness and regulatory alignment throughout the product life cycle. Together, they define the product’s value, which is delivering intelligent, efficient, and compliant solutions for our clients.

CoVigilAI streamlines pharmacovigilance by automating adverse drug event detection and reporting, and achieving 70–75 percent efficiency gains. With 99.8 percent decision accuracy ensuring no Valid event is ever missed out. Human + Machine intelligent has helped bring human error for one of our clients from 9 percent to almost at 0 percent, ensures auditability and regulatory compliance, and in turn provide cost benefits.

Beyond operational benefits, it enhances patient safety by preventing health risks and shielding companies from heavy regulatory fines. On the other hand, CliniWiseAI transforms clinical research through its innovative AI, ML and Generative AI solutions tailored for the clinical trial process. It enhances efficiency, accuracy, and insights across the entire trial lifecycle.

What are the practical implications of this solution? Could you walk us through an example?
CoVigilAI was recently implemented to streamline a high-volume literature review process, where the team manually processed 30,000–50,000 abstracts monthly to identify adverse drug events. CoVigilAI automated the entire workflow, resulting in 60–70 percent efficiency gains and with the same team size, the client can now handle up to 90,000–100,000 articles monthly, enabling scalability without additional headcount.

In another case, with AI and human-in-the-loop, a high error rate (9–10 percent) in manual reviews was reduced to almost at 0 percent, ensuring more accurate adverse event reporting, preventing regulatory fines, and enhancing patient safety by ensuring timely identification and communication of harmful drug effects.